These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 12847052)

  • 1. Rapamycin for cardiac transplant rejection and vasculopathy: one stone, two birds?
    Edelman ER; Danenberg HD
    Circulation; 2003 Jul; 108(1):6-8. PubMed ID: 12847052
    [No Abstract]   [Full Text] [Related]  

  • 2. Rapamycin slows heart transplant vasculopathy.
    SoRelle R
    Circulation; 2003 Jul; 108(1):e9001. PubMed ID: 12847063
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of rapamycin slows progression of cardiac transplantation vasculopathy.
    Mancini D; Pinney S; Burkhoff D; LaManca J; Itescu S; Burke E; Edwards N; Oz M; Marks AR
    Circulation; 2003 Jul; 108(1):48-53. PubMed ID: 12742978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs.
    Lindenfeld J; Miller GG; Shakar SF; Zolty R; Lowes BD; Wolfel EE; Mestroni L; Page RL; Kobashigawa J
    Circulation; 2004 Dec; 110(25):3858-65. PubMed ID: 15611389
    [No Abstract]   [Full Text] [Related]  

  • 5. Sirolimus: not so sparing in the Spare-the-Nephron trial.
    Shamseddin MK; Gupta A
    Kidney Int; 2011 Jun; 79(12):1379; author reply 1379-80. PubMed ID: 21625260
    [No Abstract]   [Full Text] [Related]  

  • 6. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
    Eisen HJ; Tuzcu EM; Dorent R; Kobashigawa J; Mancini D; Valantine-von Kaeppler HA; Starling RC; Sørensen K; Hummel M; Lind JM; Abeywickrama KH; Bernhardt P;
    N Engl J Med; 2003 Aug; 349(9):847-58. PubMed ID: 12944570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive approaches to the prevention of graft vascular disease.
    Gregory CR
    Transplant Proc; 1998 May; 30(3):878-80. PubMed ID: 9595134
    [No Abstract]   [Full Text] [Related]  

  • 8. Pediatric utilization of rapamycin for severe cardiac allograft rejection.
    Straatman LP; Coles JG
    Transplantation; 2000 Aug; 70(3):541-3. PubMed ID: 10949201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of splenectomy and mono- or combination therapy with rapamycin, the morpholinoethyl ester of mycophenolic acid and deoxyspergualin on cardiac xenograft survival.
    Wang J; Morris RE
    Transplant Proc; 1991 Feb; 23(1 Pt 1):699-702. PubMed ID: 1990655
    [No Abstract]   [Full Text] [Related]  

  • 10. Effects of a mycophenolate mofetil-based immunosuppressive regimen in Chagas' heart transplant recipients.
    Bestetti RB; Souza TR; Lima MF; Theodoropoulos TA; Cordeiro JA; Burdmann EA
    Transplantation; 2007 Aug; 84(3):441-2. PubMed ID: 17700175
    [No Abstract]   [Full Text] [Related]  

  • 11. An update on clinical outcomes in heart and lung transplantation.
    Garrity ER; Mehra MR
    Transplantation; 2004 May; 77(9 Suppl):S68-74. PubMed ID: 15201689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De novo immunosuppression with sirolimus and tacrolimus in heart transplant recipients compared with cyclosporine and mycophenolate mofetil: a one-year follow-up analysis.
    Zucker MJ; Baran DA; Arroyo LH; Goldstein DJ; Neacy C; Mele L; Weinberg AD; Prendergast TW; Ribner HS
    Transplant Proc; 2005 Jun; 37(5):2231-9. PubMed ID: 15964386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus therapy in cardiac transplantation.
    Radovancevic B; Vrtovec B
    Transplant Proc; 2003 May; 35(3 Suppl):171S-176S. PubMed ID: 12742492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of cardiac allograft vasculopathy with Certican (everolimus): the Stanford University experience within the Certican Phase III clinical trial.
    Valantine H
    J Heart Lung Transplant; 2005 Apr; 24(4 Suppl):S191-5; discussion S210-1. PubMed ID: 15774321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapamycin-based rescue therapy after chronic rejection in a pediatric liver transplant patient.
    Iglesias J; Ortega J; López JA; Sánchez L; Allende E; Asensio M; Margarit C
    Transpl Int; 2003 Oct; 16(10):765-7. PubMed ID: 12827229
    [No Abstract]   [Full Text] [Related]  

  • 16. Balancing efficacy and toxicity in kidney-transplant immunosuppression.
    Leichtman AB
    N Engl J Med; 2007 Dec; 357(25):2625-7. PubMed ID: 18094383
    [No Abstract]   [Full Text] [Related]  

  • 17. Sirolimus immunosuppression in pediatric heart transplant recipients: a single-center experience.
    Lobach NE; Pollock-Barziv SM; West LJ; Dipchand AI
    J Heart Lung Transplant; 2005 Feb; 24(2):184-9. PubMed ID: 15701435
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus for cardiac allograft vasculopathy--every patient, at any time?
    Patel JK; Kobashigawa JA
    Transplantation; 2011 Jul; 92(2):127-8. PubMed ID: 21555972
    [No Abstract]   [Full Text] [Related]  

  • 19. Medication management of cardiac allograft vasculopathy after heart transplantation.
    Hollis IB; Reed BN; Moranville MP
    Pharmacotherapy; 2015 May; 35(5):489-501. PubMed ID: 26011142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The management of immunosuppression: the art and the science.
    Mancini MC; Cush EM; Launius BK; Brown PA
    Crit Care Nurs Q; 2004; 27(1):61-4. PubMed ID: 14974524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.